ValidCare reports to US FDA that trials find no evidence of CBD liver toxicity

No evidence of liver toxicity from CBD has been found in the ValidCare study, the results of which have been given to the US Food and Drug Administration (FDA) for review

Read full article

Download the full news analysis

"*" indicates required fields

Corporate Email*

Company Name*

Name*

Department*

Industry*

Work Telephone*

How did you hear about us?*

Name

This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Freddie Dawson

Senior news editor

Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the CannIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

LATEST ALERTS

ValidCare reports to US FDA that trials find no evidence of CBD liver toxicity

Freddie Dawson

Our Key Benefits

Sign up to our newsletter

LATEST ALERTS

Download the full news analysis

Freddie Dawson

Our Key Benefits

Thanks for getting in touch with us

Sign up to our newsletter

Start your FREE trial